Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)

Cardiovascular Disease Clinical Trial

Official title:

Human Biospecimen Procurement and Analysis to Support Translational Research to Identify Genetic Etiology and Disease Mechanism(s) in Rare Genetic Vascular/Cardiovascular Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02543996
• Other study ID #: 150190
• Secondary ID: 15-H-0190
• Status: Recruiting
• Start date: September 17, 2015
• Est. completion date: May 22, 2050

Study information

• Verified date: May 23, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: Jayson J Grey, R.N.
• Phone: (301) 318-0338
• Email: jayson.grey[@]nih.gov
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background:

Studies show that rare genetic variants might lead to diseases. Researchers want to collect blood and tissue samples so they can study them and better understand diseases.

Objective:

To collect blood and tissue samples for studies to identify underlying causes of disease.

Eligibility:

People of all ages

Design:

Participants will have blood and/or tissue samples collected.

Samples can be collected at the NIH Clinical Center. Participants doctors can collect the samples and send them to NIH. NIH staff can collect samples off site.

For blood samples, blood is taken from an arm vein using a needle.

Tissue collection may involve:

Buccal smear: Cells are collected by scraping the inside of the cheek with a cotton swab.

Saliva collection: Participants spit into a cup.

Skin biopsy: A special needle takes a very small skin sample.

Surgical waste tissue: If participants have surgery, NIH may receive samples of tissue that

would routinely be removed.

Umbilical cord or cord blood collection: If a participant has a baby, NIH may receive a

small piece of the umbilical cord or blood from the cord once the baby is delivered.

Description:

The diversity of human research programs at the National Institutes of Health (NIH) provides a unique opportunity to study different patient populations with monogenetic and undiagnosed diseases with vascular implications. Patient populations with mutations in almost every major signaling pathway related to cardiovascular diseases are actively investigated at the NIH Clinical Center. The purpose of this protocol is to obtain and analyze human biospecimens from affected and unaffected cohorts (as reference biospecimens) to identify genetic etiology and/or underlying disease mechanism(s) in rare genetic vascular/cardiovascular conditions. The collections will consist of biospecimens obtained from participants consented under this protocol and will also provide for the continued storage and analysis of biospecimens previously obtained from NIH Institutional Review Board (IRB)-approved protocols, or from NIH protocols nearing completion. The biospecimens collected under this protocol will include blood (plasma, serum, peripheral blood mononuclear cells (PBMCs)), saliva, buccal mucosa, urine, and skin biopsies. Additional biospecimens collected under other protocols may also be transferred to this protocol, including, tissue and fluid aspirates (cerebrospinal fluid, ascites, etc.), bone marrow, urine, saliva, skin biopsies, surgical tissue waste, malignant and non-malignant tissue samples, and/or other direct derivatives from human tissues (i.e. DNA, RNA, and induced pluripotent stems cells). Post-delivery umbilical cord core blood and cord tissue waste will be collected at the time of delivery under this protocol and/or shared if obtained under other protocols. Biospecimens may also be obtained as shared samples of clinically indicated procedures done inside or outside NIH, provided the subject consents to this protocol.

The primary objective of this protocol is to create a robust resource to support basic and translational research by providing a mechanism for collecting, tracking, storing, dispensing, analyzing, and disposing of laboratory research samples from affected and unaffected cohorts. This research will advance high-quality research in the areas of genetics and personalized medicine.

As this is not a treatment protocol, there is no primary endpoint. Research studies will include, but not be limited to, genomic studies, primary cell isolation and cell culture studies for molecular and biochemical analysis, immunohistological analysis, generation of patient-specific in vitro disease models (i.e. IPSCs), etc. As science is a continuously evolving field, technological advances in research methods will be incorporated into research studies accordingly.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10000
• Est. completion date: May 22, 2050
• Est. primary completion date: June 4, 2040
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 1 Month to 100 Years

Eligibility

• INCLUSION CRITERIA (SUBJECTS MUST MEET ONE OF THE FOLLOWING):

• Age: older than 1 month of age

• Affected pregnant women if they have been referred with a known or suspected pathology or if they become pregnant while on study.

• Unaffected related pregnant women (including spouses/partners) for cord blood and tissue collection (surgical waste) only at the time of delivery.

• Cognitively impaired individuals that are affected

• Cognitively impaired individuals that are related to an affected subject.

• Subjects willing to provide informed consent.

EXCLUSION CRITERIA:

• Healthy volunteers unable to give informed consent

• Cognitively impaired individuals who are not affected

• Cognitively impaired individuals who are not related to affected subjects.

Related Conditions & MeSH terms

• Cardiovascular Disease
• Cardiovascular Diseases
• Undiagnosed Diseases

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To procure human biospecimens from affected and unaffected cohorts for on-going and future basic and translational research studies to identify underlying disease mechanism(s)	The primary objective is to procure human biospecimens from affected and unaffected cohorts for on-going and future basic translational research studies to identify underlying disease mechanism(s) and potential therapeutic approaches	ongoing

External Links

•   NIH Clinical Center Detailed Web Page